Virological Failure in HIV to Triple Therapy With Dolutegravir-Based Firstline Treatment: Rare but Possible

por Pena, M J, Chueca, N, D’Avolio, A, Zarzalejos, J M, Garcia, F
Publicado 2018

SLCO3A1 expression is a major determinant of atazanavir PBMC penetration in HIV-infected patients

por Siccardi, M, D'Avolio, A, Baietto, L, Simiele, M, Bonora, S, Back, DJ, Di Perri, G, Owen, A
Publicado 2010

Data on the stability of darunavir/cobicistat suspension after tablet manipulation

por Zanon, D., Manca, A., De Nicolò, A., D'Avolio, A., Musazzi, U.M., Cilurzo, F., Maximova, N., Tomasello, C., Minghetti, P.
Publicado 2020

Data on compounding lopinavir and ritonavir suspension for non-cooperative COVID-19 patients

por Zanon, D., Musazzi, U.M., Manca, A., De Nicolò, A., D'Avolio, A., Cilurzo, F., Maximova, N., Tomasello, C., Clementi, E., Minghetti, P.
Publicado 2020

The pharmacokinetic and safety profile of raltegravir and ribavirin, when dosed separately and together, in healthy volunteers

por Ashby, J, Garvey, LJ, Erlwein, OW, Lamba, H, Weston, R, Legg, K, McClure, MO, Dickinson, L, D'Avolio, A, Back, DJ, Winston, A
Publicado 2010

A filter-based cross-sectional analysis of an HIV-positive, HAART-treated cohort in rural Burundi: pharmacokinetics, pharmacogenetics and viral load

por Calcagno, A, Milia, MG, D'Avolio, A, Ndayishimiyae, P, Dusabimana, P, Bonora, S, Cusato, J, Simiele, M, Rostagno, R, Siccardi, M, Audagnotto, S, Ghisetti, V, Di Perri, G
Publicado 2010

Analysis of determinants of long-term efficacy of unboosted atazanavir-based regimens in the clinical setting

por Bonora, S, Calcagno, A, Viganò, O, Bigliano, P, Rusconi, S, Trentini, L, Tettoni, MC, Orofino, G, Salassa, B, Bramato, C, D'Avolio, A, Siccardi, M, Colella, E, Galli, M, Di Perri, G
Publicado 2010